d
e
ri s
o
u t h
r   a
e
g
Ivozall 
Procedural steps taken and scientific information after the authorisation 
n
o  l o
Opinion/ 
Commission 
Product 
Summary 
c t  n
Notification
1 issued on 
u
Decision 
Information 
Issued2 / 
affected3  
amended 
on 
Application 
Scope 
number 
IB/0006 
C.I.2.a - Change in the SPC, Labelling or PL of a 
d
o
r
a l  p
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
d i c i n
e
the MAH 
M
06/03/2023 
SmPC and PL 
To update section 4.6 of the SmPC to align to reference 
product to include the recommendations on the duration of 
contraception following the end of treatment with a 
genotoxic drug' and available data. Package leaflet has 
been updated accordingly. Furthermore, the MAH included 
changes for the local representative for Lithuania. 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
N/0005 
Minor change in labelling or package leaflet not 
03/11/2021 
02/12/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
PSUSA/805/2
Periodic Safety Update EU Single assessment - 
08/07/2021 
n/a 
02012 
clofarabine 
IAIN/0002/G 
This was an application for a group of variations. 
11/12/2020 
02/12/2021 
PRAC Recommendation - maintenance 
d
e
ri s
o
u t h
Annex II and 
r   a
PL 
g
e
n
o  l o
n/a 
IA/0003/G 
This was an application for a group of variations. 
10/12/2020 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
a l  p
changes to an approved test procedure 
d i c i n
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
e
M
c t  n
u
d
o
r
PSUSA/805/2
Periodic Safety Update EU Single assessment - 
23/07/2020 
17/09/2020 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
Page 2/3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
01912 
clofarabine 
the variation to terms of the Marketing Authorisation(s)’ for 
o  l o
c t  n
u
d
o
r
a l  p
d i c i n
e
M
d
e
ri s
o
PSUSA/805/201912. 
u t h
r   a
e
g
n
Page 3/3 
 
 
 
 
 
 
 
